Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea’s Celltrion Looks To Help Patients Pay For Remicade Biosimilar

This article was originally published in The Pink Sheet Daily

Executive Summary

Although the price of Celltrion’s biosimilar is lower than J&J’s Remicade, most patients will not be covered under Korea’s National Health Insurance.

Advertisement

Related Content

Korea's Celltrion Not Seeking More Sales, Distribution Deals With Big Pharma
Merck And J&J Settle Remicade Dispute By Redrawing The Map
Korea FDA Unveils Initial Biosimilar Guidance; Final Guidelines To Be Released In July
Market Snapshot: Anti-TNFs Grow Despite Tough Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074732

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel